M17
Conditions
Interventions
Group 1: -U1: baseline examination followed by daily oral intake of 10g of specific collagen peptides over a period of 24 weeks
-U2: control examination as U1 after 24 weeks
Group 2: -U1: baseline exa
Sponsors
Steinbeis-Transferzentrum 1172
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: -knee joint complaints of arthritic genesis -arthritis of the knee joint according to Kellgren-Lawrence stage II-III -no acute traumatic injury of the knee joint -no indication of inflammatory (rheumatic/bacterial/viral) genesis of the pain symptoms
Exclusion criteria
Exclusion criteria: -intra-articular injections (cortisol, hyaluronic acid, etc.) in the last 6 months -intake of chrondroprotective dietary supplements (glucoasmin, chrondroitin, etc.) in the last 6 months -intake of collagen peptides or UC-II collagen in the last 6 months -extreme pain symptoms requiring high-dose analgesic therapy over a prolonged period (>2 weeks) or intra-articular injection treatment or surgical therapy -intolerance to ingredients of the dietary supplement to be tested -no consumption of animal products or pork products -known allergy/reaction to contrast media used in medical diagnostics (especially dotarem) -known bronchial asthma or allergy -kidney disease -liver disease -past or upcoming organ transplantation -symptomatic cardiovascular disease -treatment with a beta blocker -known cramping disorder -existing pregnancy or desire to have children -very poor arm veins -metallic, magnetic and electronic implants, pacemakers, prostheses or other foreign bodies -expressed claustrophobia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -dGEMRIC index (magnetic resonance imaging (MRI), dGEMRIC procedure) (U1: 0 weeks, U2: 24 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| -assessment of knee pain during physical activity (after 12-15 stairs) by the study participant (visual analog scale (VAS)) (U1-U2: 0-24 weeks, 1x/week) -assessment of pain intensity by the study participant (WOMAC questionnaire, U1: 0 weeks, U2: 24 weeks) -documentation: daily intake, side effects, medication, other treatment options (study diary, U1-U2: 0-24 weeks) -physical activity behavior (BSA questionnaire, U1: 0 weeks, U2: 24 weeks) -nutritional behavior (dietary protocol, U1: 0 weeks, U2: 24 weeks) -body height, body weight, body mass index (BMI) (scale, tape measure) (U1: 0 weeks, U2: 24 weeks) -blood pressure (electronic blood pressure device) (U1: 0 weeks, U2: 24 weeks) -blood values (safety parameters) (blood uptake), U1: 0 weeks) | — |
Countries
Germany
Contacts
Public ContactJudith Brame
Albert-Ludwigs-Universität Freiburg, Institut für Sport und Sportwissenschaft
Outcome results
None listed